Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:10 PM
Ignite Modification Date:
2025-12-24 @ 9:10 PM
NCT ID:
NCT02830204
Eligibility Criteria:
Inclusion Criteria:
* Subject has severe native mitral annular calcification associated with mitral stenosis and/or regurgitation. Qualifying echo must be within 60 days of the date of the procedure.
* Subject has a clinical indication for mitral valve replacement, as demonstrated by reported New York Heart Association (NYHA) Functional Class II or greater.
* The subject is at least 22 years old.
* The Heart Team agrees that the subject is high risk or inoperable for surgical mitral valve repair or replacement (MVR), based on a conclusion that the probability of death or serious, irreversible morbidity exceeds the probability of meaningful improvement. The following concomitant procedures, are allowed: Maze, Tricuspid Valve Procedures (TVP), and Atrial Fibrillation (AF) ablation, coronary artery bypass grafting and septal myectomy.
* The study subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
* The study subject agrees to comply with all required post-procedure follow-up visits
Exclusion Criteria:
* Evidence of an acute myocardial infarction (MI) ≤ 30 days before the intended treatment \[defined as: Q wave MI, or non-Q wave MI with total creatine kinase (CK) elevation of creatine kinase-myocardial band (CK-MB) ≥ twice normal in the presence of myocardial band (MB) elevation and/or troponin level elevation (WHO definition)\].
* Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease).
* Leukopenia (white blood cell count \< 2000 cell/mL), acute anemia (hemoglobin \< 8 g/dL), or thrombocytopenia (platelet count \< 50,000 cell/mL).
* Hemodynamic or respiratory instability requiring vasoactive medications, mechanical ventilation at time of procedure.
* Need for emergency surgery for any reason.
* Severe left ventricular dysfunction with Left Ventricular Ejection Fraction (LVEF) \< 30%.
* Severe right ventricular dysfunction
* Pregnancy, lactation, or planning to become pregnant
* Echocardiographic evidence of left ventricular mass, thrombus, or concerns of active infective endocarditis.
* Active upper gastrointestinal (GI) bleeding within 3 months prior to procedure without treatment or 30 days prior to procedure with definitive treatment.
* A known contraindication or hypersensitivity to all anticoagulation regimens, or inability to be maintained on oral anticoagulant following the study procedure.
* End stage renal disease requiring dialysis
* Clinically (by neurologist) or neuroimaging confirmed stroke or transient ischemic attack (TIA) within 30 days of the procedure.
* Estimated life expectancy \< 12 months
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
22 Years
Study:
NCT02830204
Study Brief:
Protocol Section:
NCT02830204